Summary
Post-translational modifications are covalent alterations to proteins following biosynthesis, exponentially expanding the proteome's functional diversity. Key modifications include phosphorylation, glycosylation, ubiquitination, and lipidation.
Key Points
- 1>200 different PTM types dramatically expand proteome diversity
- 2Phosphorylation is the key regulatory switch in signaling
- 3Glycosylation critical for folding and quality control
- 4Ubiquitination controls protein degradation
Post-translational modifications (PTMs) transform the ~20,000 protein-coding genes into millions of functionally distinct protein species.
Expanding the Proteome
The genome encodes only 20 standard amino acids, but PTMs vastly expand functional diversity:
- >200 different PTM types have been identified
Major PTM Categories
Phosphorylation
The most studied regulatory modification:
- Catalyzed by kinases; removed by phosphatases
Glycosylation
Addition of carbohydrate chains:
N-linked glycosylation
O-linked glycosylation
Ubiquitination
Attachment of ubiquitin protein:
- Monoubiquitination: Endocytosis, DNA repair
- K48-polyubiquitination: Targets for proteasomal degradation
- K63-polyubiquitination: Signaling, autophagy
Lipidation
Attachment of lipid groups:
- Myristoylation: 14-carbon fatty acid
- Palmitoylation: 16-carbon fatty acid (reversible)
- Prenylation: Isoprenoid groups
Other Important PTMs
- Acetylation: Neutralizes positive charge of Lys
- Methylation: Lys, Arg (especially on histones)
- SUMOylation: SUMO protein attachment
- ADP-ribosylation: Regulatory modification
Functional Consequences
PTMs alter protein properties:
- Charge: Phosphorylation, acetylation
- Hydrophobicity: Lipidation
- Steric bulk: Glycosylation, ubiquitination
- Conformation: Can induce structural changes
- Stability: Ubiquitination targets for degradation
- Localization: Lipidation anchors to membranes
- Interactions: Create or disrupt binding sites
PTMs and Disease
Dysregulation of PTMs underlies many diseases:
- Cancer: Aberrant kinase signaling
- Diabetes: Insulin signaling defects
- Neurodegeneration: Tau hyperphosphorylation, protein aggregation
- Congenital disorders: Glycosylation defects